Atai Life Sciences is a biotechnology business based in the US. Atai Life Sciences stocks (ATAI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.4 – a decrease of 11.41% over the previous week. Atai Life Sciences employs 35 staff and has a trailing 12-month revenue of around $20.1 million.
How to buy shares in Atai Life Sciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ATAI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Atai Life Sciences stock price (NASDAQ:ATAI)Use our graph to track the performance of ATAI stocks over time.
Atai Life Sciences shares at a glance
|Latest market close||$4.66|
|52-week range||$4.66 - $22.91|
|50-day moving average||$9.19|
|200-day moving average||$13.72|
|Wall St. target price||$28.46|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.94|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Atai Life Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Atai Life Sciences price performance over time
|1 week (2022-01-21)||-11.41%|
|1 month (2021-12-28)||-36.43%|
|3 months (2021-10-28)||-67.14%|
|6 months (2021-07-28)||-71.29%|
|1 year (2021-01-24)||N/A|
|2 years (2020-01-24)||N/A|
|3 years (2019-01-24)||N/A|
|5 years (2017-01-24)||N/A|
Atai Life Sciences financials
|Revenue TTM||$20.1 million|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$823.9 million|
TTM: trailing 12 months
Atai Life Sciences share dividends
We're not expecting Atai Life Sciences to pay a dividend over the next 12 months.
Atai Life Sciences overview
Atai Life Sciences N. V. , through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.
Atai Life Sciences in the news
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study - Benzinga
Atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Silver Spike Investment Corp. (SSIC) stock in Canada when it goes public
Everything we know about the Silver Spike Investment Corp. IPO, plus information on how to buy in.
How to buy MOD Pizza stock in Canada when it goes public
Everything we know about the MOD Pizza IPO, plus information on how to buy in.
How to buy Modular Medical (MODD) stock in Canada when it goes public
Everything we know about the Modular Medical IPO, plus information on how to buy in.
How to buy Direct Digital Holdings (DRCT) stock in Canada when it goes public
Everything we know about the Direct Digital Holdings IPO, plus information on how to buy in.
How to buy TC BioPharm (TCBP) stock in Canada when it goes public
Everything we know about the TC BioPharm IPO, plus information on how to buy in.
How to buy Maris-Tech Ltd (MTEK) stock in Canada when it goes public
Everything we know about the Maris-Tech Ltd IPO, plus information on how to buy in.
How to buy Phoenix Motor (PEV) stock in Canada when it goes public
Everything we know about the Phoenix Motor IPO, plus information on how to buy in.
How to buy Nauticus Robotics, Inc. (KITT) stock in Canada when it goes public
Everything we know about the Nauticus Robotics, Inc. IPO, plus information on how to buy in.
What is Mogo and how can you access its new trading platform, MogoTrade? Find out in our review.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Ask an Expert
You must be logged in to post a comment.